Literature DB >> 15829264

The BAFF/APRIL system: life beyond B lymphocytes.

Lai Guan Ng1, Charles R Mackay, Fabienne Mackay.   

Abstract

B cell activating factor belonging to the TNF family (BAFF) and a proliferation-inducing ligand (APRIL) are two members of the TNF ligand superfamily. Studies of BAFF, APRIL and their receptors have highlighted the importance of this ligand/receptor system in regulating B cell homeostasis, tolerance and malignancy. Neutralizing BAFF can inhibit disease progression in animal models of autoimmunity, possibly by reducing survival of autoreactive B cells. In addition, BAFF inhibitors also prevent B lymphoma cell survival and may be useful for the treatment of lymphoid cancers. Recent work suggests that BAFF is also important for T cell activation and differentiation, an aspect that may be critical for the progression of certain autoimmune diseases. Therefore, targeting the BAFF/APRIL system may protect against autoimmunity and lymphoid cancers through the inhibition of pathogenic B and T cell functions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15829264     DOI: 10.1016/j.molimm.2004.06.041

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  51 in total

1.  Cerebrospinal fluid BAFF and APRIL levels in neuromyelitis optica and multiple sclerosis patients during relapse.

Authors:  Honghao Wang; Kai Wang; Xiaonan Zhong; Wei Qiu; Yongqiang Dai; Aimin Wu; Xueqiang Hu
Journal:  J Clin Immunol       Date:  2012-05-30       Impact factor: 8.317

2.  Immune receptor expressed on myeloid cells 1 (IREM-1) inhibits B cell activation factor (BAFF)-mediated inflammatory regulation of THP-1 cells through modulation of the activities of extracellular regulated kinase (ERK).

Authors:  S-M Lee; Y-P Nam; K Suk; W-H Lee
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

3.  Decreased B cell activating factor receptor expression on peripheral lymphocytes associated with increased disease activity in primary Sjögren's syndrome and systemic lupus erythematosus.

Authors:  Jérémie Sellam; Corinne Miceli-Richard; Jacques-Eric Gottenberg; Marc Ittah; Frédéric Lavie; Christine Lacabaratz; Nicolas Gestermann; Alexis Proust; Olivier Lambotte; Xavier Mariette
Journal:  Ann Rheum Dis       Date:  2006-12-21       Impact factor: 19.103

Review 4.  Microarray-based understanding of normal and malignant plasma cells.

Authors:  John De Vos; Dirk Hose; Thierry Rème; Karin Tarte; Jérôme Moreaux; Karéne Mahtouk; Michel Jourdan; Hartmut Goldschmidt; Jean-François Rossi; Friedrich W Cremer; Bernard Klein
Journal:  Immunol Rev       Date:  2006-04       Impact factor: 12.988

Review 5.  Translational Mini-Review Series on B Cell-Directed Therapies: B cell-directed therapy for autoimmune diseases.

Authors:  C Hu; F S Wong; L Wen
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

6.  BAFF and APRIL induce inflammatory activation of THP-1 cells through interaction with their conventional receptors and activation of MAPK and NF-κB.

Authors:  Sang-Min Lee; Eun-Ju Kim; Kyoungho Suk; Won-Ha Lee
Journal:  Inflamm Res       Date:  2011-04-20       Impact factor: 4.575

Review 7.  Midkine as a regulator of B cell survival in health and disease.

Authors:  Sivan Cohen; Idit Shachar
Journal:  Br J Pharmacol       Date:  2014-02       Impact factor: 8.739

8.  Myeloid cells, BAFF, and IFN-gamma establish an inflammatory loop that exacerbates autoimmunity in Lyn-deficient mice.

Authors:  Patrizia Scapini; Yongmei Hu; Ching-Liang Chu; Thi-Sau Migone; Anthony L Defranco; Marco A Cassatella; Clifford A Lowell
Journal:  J Exp Med       Date:  2010-07-12       Impact factor: 14.307

9.  Cell to Cell Interaction Can Activate Membrane-bound APRIL Which Are Expressed on Inflammatory Macrophages.

Authors:  Sang-Min Lee; Won-Jung Kim; Kyoungho Suk; Won-Ha Lee
Journal:  Immune Netw       Date:  2010-10-31       Impact factor: 6.303

10.  Differential requirement of MALT1 for BAFF-induced outcomes in B cell subsets.

Authors:  Michael W Tusche; Lesley A Ward; Frances Vu; Doug McCarthy; Miguel Quintela-Fandino; Jurgen Ruland; Jennifer L Gommerman; Tak W Mak
Journal:  J Exp Med       Date:  2009-11-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.